Dr. Soumerai is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Massachusetts General Hospital
55 Fruit Street
Boston, MA 02114Phone+1 617-724-4000
Summary
- Dr. Jacob Soumerai is an oncologist in Boston, MA and is affiliated with Massachusetts General Hospital. He received his medical degree from Tufts University School of Medicine and has been in practice at the MGH Cancer Center since 2017. He specializes in hematologic oncology and is experienced in chronic lymphoid leukemia and lymphoma.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2014 - 2017
Massachusetts General HospitalResidency, Internal Medicine, 2011 - 2014
Tufts University School of MedicineClass of 2011
Certifications & Licensure
MA State Medical License 2013 - 2026
NH State Medical License 2024 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Inductee Alpha Omega Alpha Honor Medical Society, 2011
Clinical Trials
- Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma Start of enrollment: 2019 Sep 01
- Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL Start of enrollment: 2020 Oct 19
- Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL Start of enrollment: 2020 Dec 15
- Join now to see all
Publications & Presentations
PubMed
- 8 citationsNext-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma.Jacob D Soumerai, Allison Rosenthal, Shannon Harkins, Jessica Duffy, Carmen Mecca
Blood. 2022-10-20 - 31 citationsEffect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma.Kevin Charles Miller, Patrick Connor Johnson, Jeremy S Abramson, Jacob D Soumerai, Andrew J Yee
Blood Cancer Journal. 2022-11-01 - 200 citationsClinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cellsPhilipp Karschnia, Justin T. Jordan, Deborah Forst, Isabel Arrillaga-Romany, Tracy T. Batchelor
Blood. 2019-05-16
Abstracts/Posters
- A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLLA Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or R...Jacob D. Soumerai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Time to Second Treatment As a Proxy for Overall Survival in CLL/SLL: Identifying Risk Factors to Help Guide Treatment SelectionJacob D. Soumerai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisoc...Jacob D. Soumerai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Press Mentions
IgG Testing, Immunoglobulin Replacement Therapy Improve Infection Outcomes in CLL, NHLAugust 16th, 2024- ASH 2022: MCL Trials Break New Ground, May Change PracticeJanuary 30th, 2023
- ‘Highly Encouraging’ MRD Results for Zanubrutinib Add-on in CLLJanuary 12th, 2022
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
